RECITAL trial: First line RTX vs. CYC in ILD 🫁 asso w/ SSc, mixed CTD or Myositis.
Primart endpoint FVC 24 wks improved in both mCTD and Myositis associated ILD but only stabilized in SSc-ILD. RTX improved skin thickness 24 wks. https://t.co/MQcqds0jYA
Abst#0003 #ACR22 @Rheumnow https://t.co/pK48716nIg
Links:
Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Diseas…
http://bit.ly/3WRXQUU
12-11-2022
